Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor for the treatment of Moderate to Severe Rheumatoid Arthritis.
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor for the treatment of Moderate to Severe Rheumatoid Arthritis.
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2023
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 (zunsemetinib) is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 inhibitor. This mechanism potentially leads to the inhibition of inflammatory signals. It is being developed for rheumatoid arthritis and psoria...
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : Zunsemetinib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-450 resulted in inhibition of TNF?, IL1?, IL8, and IL6, was generally well-tolerated at all doses tested in the trial; had no significant food effect or drug-drug interaction with methotrexate.
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA Allows IND to study ATI-450 in hospitalized patients with COVID-19. Aclaris is supporting an investigator-initiated trial of ATI-450 for cytokine release syndrome in 36 hospitalized patients with COVID-19, and will provide funding and clinical drug s...
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : Zunsemetinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris Therapeutics Announces Publication of the Phase 1 Clinical Trial Results for ATI-450
Details : Abstract highlights data from a Phase 1 study in healthy volunteers exploring the safety, pharmacokinetics and pharmacodynamics of ATI-450, a novel oral MK2 inhibitor.
Product Name : ATI-450
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2020
Lead Product(s) : Zunsemetinib,Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable